About Sphaera Pharma Research and Development Private Limited
Data last updated:
Sphaera Pharma Research and Development Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 28 November 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2008PTC224719. Its GSTIN is 06AAMCS5712L1Z0 (Haryana).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1.95 Lakh. It is led by directors Abhinav Dhandia and Ashish Dugar.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A – 5/110 Indra Enclave Neb Sarai, New Delhi, Delhi, India – 110068.
As per the financials filed for FY 2025, the company reported a revenue of ₹67,500, a decline of 83% compared to the previous year. For the same year it recorded a net loss of ₹2.8 Lakh (net margin -415.2%) and EBITDA of -₹2.8 Lakh (EBITDA margin -415.2%). Revenue has declined at a compounded annual rate (CAGR) of 56% over three years and 48% over five years.
The company is associated with 1 brand: Sphaera Pharma. As per MCA filings, the company has satisfied charges of ₹1.19 Cr on record. The company has 3 deals on record (3 secondary share transfers); the latest was in September 2015. Its 3 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 2 larger and 1 smaller; the largest is Novelgenix Therapeutics Private Limited with revenue of ₹93,183.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sphaerapharma.com.
Company details
CIN history
Sphaera Pharma Research and Development has one previous CIN (Corporate Identification Number): U24232RJ2008PTC027855. The current CIN is U24232DL2008PTC224719, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232DL2008PTC224719 | Current |
| U24232RJ2008PTC027855 | Previous |
Contact details
Sphaera Pharma Research and Development Private Limited's registered office is in New Delhi, Delhi. Its website is sphaerapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA – 5/110 Indra Enclave Neb Sarai, New Delhi, Delhi, India – 110068
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Sphaera Pharma Research and Development Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Sphaera Pharma Research and Development operates one associated brand: Sphaera Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Specialty company engaged in drug discovery and development | sphaerapharma.com |
Business activity
The main business activity of Sphaera Pharma Research and Development is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Sphaera Pharma Research and Development Private Limited, buy the company report.
Financials of Sphaera Pharma Research and Development Private Limited
FY 2025 filings availableSphaera Pharma Research and Development Private Limited reported revenue of ₹67,500 (down 83% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 48% over five years, including a 83% fall in the latest year. EBITDA fell 228% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2.8 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.8 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -415.2% | ||||
| Net Profit Margin | -415.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Sphaera Pharma Research and Development Private Limited, buy the company report.
Board of directors of Sphaera Pharma Research and Development Private Limited
Sphaera Pharma Research and Development has 2 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Abhinav Dhandia Also directs: Dhandia Jewellers LLP, Sphaera Pharma Private Limited, Cyro Healthcare Private Limited and 3 more | Director | 08 Jan 2013 | 13 Years 9 Months | Current |
| Ashish Dugar | Director | 02 Dec 2022 | 3 Years 10 Months | Current |
Peer comparison
Sphaera Pharma Research and Development Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Novelgenix Therapeutics Private Limited | ₹93,183 (FY 2025) | -98.0% | Ahmedabad, Gujarat, India | |||
| Aryastha Life Sciences Private Limited | ₹84,463 (FY 2024) | Hyderabad, Telangana, India | ||||
| Sphaera Pharma Research and Development Private Limitedthis company | ₹67,500 (FY 2025) | -₹2.8 Lakh | -415.2% | -83.0% | New Delhi, Delhi, India | |
| Gomi'da Private Limited | ₹63,000 (FY 2024) | -96.0% | Noida, Uttar Pradesh, India |
To see the full peer comparison of Sphaera Pharma Research and Development Private Limited, buy the company report.
Auditor
Sphaera Pharma Research and Development Private Limited is audited by KJAG & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| KJAG & Associates | FY 2023 | 026179N |
Shareholding
The shareholding of Sphaera Pharma Research and Development Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Sphaera Pharma Research and Development Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 Dec 2011 | 10324013 | Biotechnology Industry Research Assistance Council | ₹1.19 Cr | Satisfied |
To see the full charge records of Sphaera Pharma Research and Development Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Sphaera Pharma Research and Development Private Limited has 3 deals on record (3 secondary share transfers); the latest was in September 2015.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2015 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Sep 2011 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Sep 2010 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Sphaera Pharma Research and Development Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Sphaera Pharma Research and Development Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Sphaera Pharma Research and Development has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AAMCS5712L1Z0 | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Sphaera Pharma Research and Development Private Limited, buy the company report.
Recent activity
Sphaera Pharma Research and Development Private Limited has 12 board changes on record since 2009: 2 appointments and 10 cessations. The latest: Ashish Dugar ceased to be Additional Director on 25 Sep 2023.
6 earlier events are in the company report.
News
Frequently asked questions
Sphaera Pharma Research and Development is an active private limited company based in New Delhi, Delhi, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 28 November 2008 (18+ years old) and is registered under CIN U24232DL2008PTC224719.
Sphaera Pharma Research and Development has 2 current directors:
- Abhinav Dhandia - Director
- Ashish Dugar - Director
The latest financial statements of Sphaera Pharma Research and Development on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Sphaera Pharma Research and Development is 06AAMCS5712L1Z0, registered in Haryana.
The CIN (Corporate Identification Number) of Sphaera Pharma Research and Development is U24232DL2008PTC224719. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sphaera Pharma Research and Development was incorporated on 28 November 2008, making it 18+ years old. It is registered with the Registrar of Companies, Delhi.
Sphaera Pharma Research and Development has 3 deals on record (3 secondary share transfers); the latest was in September 2015.
The peers of Sphaera Pharma Research and Development by revenue are Novelgenix Therapeutics Private Limited, Aryastha Life Sciences Private Limited, Gomi'da Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Ashish Dugar ceased to be Additional Director on 25 Sep 2023. Ashish Dugar was appointed as Director on 02 Dec 2022. Somdutta Sen ceased to be Additional Director on 30 Oct 2021. Sphaera Pharma Research and Development has 12 board changes on record in total.
Sphaera Pharma Research and Development can be reached through the website sphaerapharma.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Sphaera Pharma Research and Development is at A – 5110 Indra Enclave Neb Sarai, New Delhi, Delhi, India – 110068.